Thiogenesis Therapeutics Corp. (TTI : TSX-V)
Common Stock
$0.60
CAD
-0.02 (-3.23%)
Last updated: 2026-06-02
TTI
Thiogenesis Therapeutics Corp.
WealthAwesomePerformance
1 Day
-3.23%
1 Week
+0.00%
1 Month
+17.65%
YTD
-7.69%
Key Statistics
Market Cap
$31.10M
52W High
$0.88
52W Low
$0.44
P/E Ratio
-
50 Day MA
$0.55
200 Day MA
$0.62
Beta
0.53
Dividend Yield
-
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 6/2/2026 | $0.62 | $0.62 | $0.60 | $0.60 | $0.60 | 8,500 |
| 6/1/2026 | $0.60 | $0.62 | $0.60 | $0.62 | $0.62 | 10,500 |
| 5/29/2026 | $0.57 | $0.60 | $0.57 | $0.60 | $0.60 | 9,500 |
| 5/28/2026 | $0.61 | $0.61 | $0.61 | $0.61 | $0.61 | 2,000 |
| 5/27/2026 | $0.60 | $0.60 | $0.60 | $0.60 | $0.60 | 5,000 |
| 5/26/2026 | $0.60 | $0.60 | $0.60 | $0.60 | $0.60 | 1,000 |
| 5/25/2026 | $0.60 | $0.60 | $0.60 | $0.60 | $0.60 | 0 |
| 5/22/2026 | $0.56 | $0.60 | $0.56 | $0.60 | $0.60 | 24,500 |
| 5/21/2026 | $0.56 | $0.56 | $0.56 | $0.56 | $0.56 | 30,000 |
| 5/20/2026 | $0.56 | $0.56 | $0.56 | $0.56 | $0.56 | 0 |
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on TTI's historical volatility
30-Day Vol
49.7%
Annualized
90-Day Vol
71.0%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$0.72
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.64 | C$0.54 – C$0.76 |
| 60 trading days | C$0.68 | C$0.53 – C$0.86 |
| 90 trading days | C$0.72 | C$0.53 – C$0.97 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Thiogenesis Therapeutics Corp.
Thiogenesis Therapeutics, Corp., a clinical-stage biopharmaceutical company, develops thiol-based therapeutic compounds to treat unmet pediatric medical needs. Its lead product candidate is TTI-0102, a prodrug that consists of cysteamine for use in the treatment of mitochondrial encephalopathy lactic acidosis and stroke-like episodes, leigh syndrome, pediatric metabolic dysfunction-associated steatohepatitis, and rett syndrome. The company is headquartered in Toronto, Canada.
Financials
- Revenue (TTM)
- $0
- EBITDA
- -
- Profit Margin
- 0.00%
- ROE (TTM)
- -724.21%
- EPS (Diluted)
- -0.14
- Book Value
- 0.04
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
Advertisement
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Common Questions About TTI
Articles Featuring TTI.V
Latest articles and analysis covering TTI.V
